Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
25 avr. 2024 08h30 HE
|
Starton Therapeutics
Phase 1b data in the first 50% of patients reflect the responses seen in animals and may suggest superiority in both safety and efficacy when compared to oral Revlimid®Anticipate FDA alignment and...
Starton Therapeutics to Present at Upcoming MedInvest and Needham Conferences
25 mars 2024 08h00 HE
|
Starton Therapeutics
PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Starton Therapeutics to Present at BIO CEO & Investor Conference 2024
23 févr. 2024 14h48 HE
|
Starton Therapeutics
PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
14 févr. 2024 13h48 HE
|
Starton Therapeutics
Regional Medical Oncology Center is activated and open to screen patientsStudy enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously...
Starton Therapeutics Announces STARTICLES Filing
17 janv. 2024 15h12 HE
|
Starton Therapeutics
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton...
Starton Therapeutics Announces Initial Key Safety and Efficacy Signals with STAR-LLD in Patients with Relapsed or Refractory Multiple Myeloma
03 janv. 2024 15h46 HE
|
Starton Therapeutics
Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment is expected by Q3/24Early data may suggest superiority in safety compared to oral Revlimid No...
Starton Therapeutics Announces the Launch of STARSILON a Novel Proprietary Transdermal PATCH Delivery Platform
02 janv. 2024 14h00 HE
|
Starton Therapeutics
Novel platform technology potentially expands the number of active pharmaceutical ingredients that can be delivered transdermallyTechnology offers a unique approach to maintaining concentration...
Starton Therapeutics to Present at Biotech Showcase 2024 in San Francisco
18 déc. 2023 08h00 HE
|
Starton Therapeutics
PARAMUS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (the “Company”) a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary...
Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment
20 nov. 2023 08h00 HE
|
Starton Therapeutics
Two patients have been dosed and a third is in screeningThe first patient has completed cycle 1 successfully where he obtained a measurable response with a decrease in M-protein from 1.7 to 0.9 gm/dL...